Advertisement

Topics

Cell Therapeutics Limited (UK) Company Profile

11:30 EST 16th December 2018 | BioPortfolio

At CTI, we're taking a different approach to the treatment of cancer—one focused on developing, acquiring, and commercializing therapies to combat the disease without compromising patient quality of life. Our goal is safer, more effective cancer therapies that can make a meaningful difference to millions.

Frequent conversations with medical professionals and their patients, financial analysts, media representatives and our own employees, have helped us design a Web site that we hope provides the information you seek. Our site includes general corporate information, descriptions of research advances, marketed drugs and product candidates, patient information, and career opportunities. Please explore our site to discover the innovation of our technologies and the commitment of our employees to making cancer a more treatable disease.

Location

1 Ropemaker Street
London
EC2Y 9HT
United Kingdom

Contact

Phone: +44 (0) 208 895 4004
Fax: +44 (0) 208 894 4204
Email: gacton@ctiseattle.com


News Articles [2233 Associated News Articles listed on BioPortfolio]

Autolus Therapeutics Announces Update on its Novel CAR T Cell Program for Peripheral T Cell ...

LONDON, Dec. 1, 2018 /PRNewswire/ -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of Re...

Rubius Therapeutics Looks to Raise $200 Million in IPO for Red-Cell Therapies

Three months after securing $100 million in a crossover financing round, Cambridge, Mass.-based Rubius Therapeutics is looking at a $200 million initial public offering to support its personalized red...

Researchers demonstrate integrated technique to control production of cell therapeutics

Researchers have demonstrated an integrated technique for monitoring specific biomolecules - such as growth factors - that could indicate the health of living cell cultures produced for the burgeoning...

BrainStorm Cell Therapeutics Announces Positive Interim Safety Analysis

On Thursday (August 23), BrainStorm Cell Therapeutics announced its Phase 3 trial for NurOwn in patients with ALS will be able to continue with no changes. The post BrainStorm Cell Therapeutics Announ...

Pluristem Therapeutics Announces FDA Orphan Drug Designation for PLX cell therapy

Pluristem Therapeutics (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced that the U.S. Food and Drug Administra...

A Hat Trick Of Cell And Gene Therapy IPOs: AVRO, MGTA, and UMRX

Last week, AvroBio and Magenta Therapeutics priced their IPOs on the same night. Less than three months earlier, Unum Therapeutics priced its IPO. All three are cell and gene therapy biotechs. The au...

Gamida Cell files for US IPO

Israeli cell therapeutics firm Gamida Cell Ltd. filed for its initial public offering on the Nasdaq Global Market.

Rubius Therapeutics to Acquire Manufacturing Facility in Smithfield, Rhode Island to Produce Red Cell Therapeutics

CAMBRIDGE, Mass., July 25, 2018 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a biotechnology company pioneering the development of a new class of ready-to-use cellular therapies, to...

PubMed Articles [3233 Associated PubMed Articles listed on BioPortfolio]

Assessing the Effects of Ripasudil, a Novel Rho Kinase Inhibitor, on Human Corneal Endothelial Cell Health.

To determine how the Rho kinase inhibitor, ripasudil, affects metabolic function and cell viability in donor human corneal endothelial cells (HCECs).

Curing cancer by cancer function.

Cancer is the disease which exists when the cell is uncontrolled. This paper presents a controller for the same. The cancer cell is reviewed via algebraic structures.

Dysregulating ClpP: From Antibiotics to Anticancer?

In this issue of Cell Chemical Biology, Wong et al. (2018) identify several dysregulators of a key mitochondrial protease: casein lytic protease P (ClpP). These dysregulators were found to trigger pr...

RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape.

Axicabtagene ciloleucel (Yescarta) for B-cell lymphoma.

Clinical Trials [6628 Associated Clinical Trials listed on BioPortfolio]

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

Autologous Unselected Hematopoietic Stem Cell Transplantation for Refractory Crohn's Disease

This study evaluates the safety and clinical benefits of a therapeutics approach of conditioning regimen Cyclophosphamide (Cy) + Thymoglobulin r (ATG) + Granulocyte Colony-Stimulating Fact...

Companies [2272 Associated Companies listed on BioPortfolio]

Magenta Therapeutics

Magenta Therapeutics is a biotechnology company harnessing the power of stem cell science to revolutionize stem cell transplantation for patients with immune- and blood-based dise...

Immunocore Limited

Immunocore Limited is developing innovative biological therapeutics to treat a range of cancers, chronic viral infections and diabetes. Immunocore is a privately owned biotechnology company located ...

Jnana Therapeutics Inc.

Jnana Therapeutics is a biotechnology company creating the first drug discovery platform to unlock the solute carrier (SLC) family of metabolite transporters as a therapeutic targ...

Opsis Therapeutics

Opsis Therapeutics is a company focused on discovering and developing new medicines to restore vision to patients suffering from retinal diseases. By combining recent innovations ...

Stem Cell Therapeutics Corp.

Stem Cell Therapeutics is a publicly listed Canadian biotechnology company headquartered in Calgary, Alberta. The company is focused on the development and commercialization of Therapeutics that contr...

More Information about "Cell Therapeutics Limited (UK)" on BioPortfolio

We have published hundreds of Cell Therapeutics Limited (UK) news stories on BioPortfolio along with dozens of Cell Therapeutics Limited (UK) Clinical Trials and PubMed Articles about Cell Therapeutics Limited (UK) for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Cell Therapeutics Limited (UK) Companies in our database. You can also find out about relevant Cell Therapeutics Limited (UK) Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...


Corporate Database Quicklinks



Searches Linking to this Company Record